Table 1 Clinical details.
From: Menstrual flow as a non-invasive source of endometrial organoids
Sample ID | Outcome | Previous obstetric history | BMI | Age | Treatment | Drug protocol |
|---|---|---|---|---|---|---|
B55 | Not pregnant | Para 0 + 0 | 30.48 | 39 | ICSI; two cleavage stage embryos transferred (2c, 4c) on Day 2 | Antagonist + gonadotrophin |
B60 | Elective CS @ 37 wks, Twins (2900 g & 2300 g) | Para 1 + 0 | 17.01 | 39 | ICSI; two blastocysts transferred on Day 5 | Agonist + gonadotrophin |
B61 | Not pregnant | Para 0 + 0 | 26.4 | 33 | FET Single BT, Day 5 | HRT |
B70 | Live Birth, 38 + 2 wks (3657 g) | Para 0 + 2EPL | 19.96 | 27 | FET; two blastocysts transferred Day 5 | HRT |
B72 | Not pregnant | Para 1 + 0 | 25.47 | 37 | IVF; 2 compacting morulae transferred on D5 | Antagonist + gonadotrophin |
B74 | Unknown | Para 1 + 1EPL | Not recorded | 49 | For IVF Rx in Cyprus | unknown |
B75 | EPL @ 7 wks | Para 0 + 0 | 30.06 | 41 | ICSI; one 4-cell embryo transferred on Day 2 | Antagonist + gonadotrophin |
